{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+hematopoietic+stem+cell+transplantation+%28allo-HSCT%29", "query": { "intervention": "Allogeneic hematopoietic stem cell transplantation (allo-HSCT)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 140, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+hematopoietic+stem+cell+transplantation+%28allo-HSCT%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-10T15:46:15.162Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01181271", "title": "Tandem Auto-Allo Transplant for Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse, Large B-Cell, Lymphoma", "Lymphoma, Low-Grade", "T-Cell Lymphoma", "Mantle-Cell Lymphoma", "Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "Busulfan (conditioning for AUTO transplant)", "type": "DRUG" }, { "name": "Etoposide (conditioning for AUTO transplant)", "type": "DRUG" }, { "name": "Cyclophosphamide (conditioning for AUTO transplant)", "type": "DRUG" }, { "name": "Mesna (prior to AUTO transplant)", "type": "DRUG" }, { "name": "autologous (auto) peripheral blood stem cell transplantation", "type": "OTHER" }, { "name": "Neupogen", "type": "DRUG" }, { "name": "Fludarabine (conditioning for ALLO Transplant)", "type": "DRUG" }, { "name": "Busulfan (conditioning for ALLO Transplant)", "type": "DRUG" }, { "name": "non-myeloablative allogeneic (allo) transplant", "type": "OTHER" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 42, "start_date": "2010-08", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-10-10T15:46:15.162Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01181271" }, { "nct_id": "NCT00350818", "title": "Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome", "Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 90, "start_date": "2005-10", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2012-07-30", "last_synced_at": "2026-10-10T15:46:15.162Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00350818" }, { "nct_id": "NCT03151057", "title": "Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B Cells-Tumors", "B Cell Chronic Lymphocytic Leukemia", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)" ], "interventions": [ { "name": "Idelalisib 100 MG", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2018-07-31", "completion_date": "2022-07-20", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-10T15:46:15.162Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03151057" }, { "nct_id": "NCT01033552", "title": "Biochemical Correction of Severe EB by Allo HSCT and \"Off-the-shelf\" MSCs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epidermolysis Bullosa" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Anti-thymocyte globulin", "type": "DRUG" }, { "name": "Myeloablative Busulfan", "type": "DRUG" }, { "name": "Mesenchymal stem cell transplantation", "type": "PROCEDURE" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Bone marrow or umbilical cord blood (UCG) stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 32, "start_date": "2010-01", "completion_date": "2021-08-12", "has_results": true, "last_update_posted_date": "2024-04-03", "last_synced_at": "2026-10-10T15:46:15.162Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01033552" }, { "nct_id": "NCT01904175", "title": "Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hodgkin's Disease", "Non Hodgkin's Lymphoma", "Myeloma", "Leukemia", "Myelodysplasia" ], "interventions": [], "intervention_types": [], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2013-08", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-05-05", "last_synced_at": "2026-10-10T15:46:15.162Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01904175" }, { "nct_id": "NCT01701986", "title": "Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematopoietic Cell Transplantation Recipient", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma", "Refractory T-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Allogeneic Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 64, "start_date": "2012-10-25", "completion_date": "2024-06-05", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-10-10T15:46:15.162Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01701986" }, { "nct_id": "NCT05201183", "title": "A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Fludarabine + Total Marrow Irradiation", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Naoyuki G. Saito, M.D., Ph.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-10", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2023-12-11", "last_synced_at": "2026-10-10T15:46:15.162Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05201183" }, { "nct_id": "NCT00004143", "title": "Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Anemia", "Severe Aplastic Anemia", "Paroxysmal Nocturnal Hemoglobinuria (PNH)", "Pure Red Cell Aplasia" ], "interventions": [ { "name": "Campath, Chemo and/or TBI Allo SCT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Rizzieri, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "1999-09", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2014-12-05", "last_synced_at": "2026-10-10T15:46:15.162Z", "location_count": 2, "location_summary": "Orlando, Florida • Durham, North Carolina", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004143" }, { "nct_id": "NCT01008462", "title": "Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Prolymphocytic Leukemia", "Hypodiploidy", "Loss of Chromosome 17p", "Plasma Cell Leukemia", "Progression of Multiple Myeloma or Plasma Cell Leukemia", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Non-Hodgkin Lymphoma", "Recurrent Childhood Hodgkin Lymphoma", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Refractory Small Lymphocytic Lymphoma", "t(14;16)", "t(4;14)", "T-Cell Prolymphocytic Leukemia", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Allogeneic Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 16, "start_date": "2010-03-18", "completion_date": "2018-06-30", "has_results": true, "last_update_posted_date": "2019-06-11", "last_synced_at": "2026-10-10T15:46:15.162Z", "location_count": 2, "location_summary": "Seattle, Washington • Milwaukee, Wisconsin", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01008462" }, { "nct_id": "NCT02646839", "title": "KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "CliniMacs TCR alpha-beta-Biotin system", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Michael Pulsipher", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 50, "start_date": "2015-10", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-10-10T15:46:15.162Z", "location_count": 11, "location_summary": "Los Angeles, California • Oakland, California • Palo Alto, California + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02646839" } ] }